Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04631133

LISA Post Market Clinical Follow-Up Study: Documentation of Clinical Outcomes After Surgery With LISA Implant

LISA Post Market Clinical Follow-Up Study:Post Marketing Prospective Documentation of Clinical Outcomes (Post-operative, Safety and Performance) After Lumbar Dynamic Stabilization Surgery With LISA Implant

Status
Recruiting
Phase
Study type
Observational
Enrollment
136 (estimated)
Sponsor
BACKBONE · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study is a post-market surveillance study of the Lumbar Implant for Stiffness Augmentation (LISA), a medical device, which is used to treat low-back pain that accompanies degenerative lesions of grades II, III, and IV (Pfirrmann MRI classification). "Post-market" means the device (i.e. the LISA implant) being used in this study has already obtained CE certification and is commercially available for use in the European market. The LISA device consists of 3 components: A PEEK interspinous spacer, a polyester band, and a titanium blocker. The spacer is positioned between two adjacent spinous processes, the band is belted around the spinous processes and through the spacer, and the blocker is used to lock the band inside the spacer. Medical Device manufacturers conduct "post-market" clinical studies in order to continuously evaluate the product scientifically and to comply with legal and ethical obligations. With these studies, the long-term safety as well as performance of their medical devices are assessed. This study, which is initiated and sponsored by BACKBONE (LISA designer, developer, manufacturer and marketer), aims to evaluate the long-term safety and performance of the LISA implant for the treatment of lumbar degenerative disease and to evaluate the treatment.

Conditions

Interventions

TypeNameDescription
DEVICELumbar Implant for Stiffness Augmentation (LISA)The LISA Posterior Dynamic Stabilization System is intended to treat low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification).

Timeline

Start date
2019-04-17
Primary completion
2024-12-31
Completion
2028-12-31
First posted
2020-11-17
Last updated
2022-07-21

Locations

5 sites across 3 countries: Denmark, France, Germany

Source: ClinicalTrials.gov record NCT04631133. Inclusion in this directory is not an endorsement.